drugset / Trial / NCT02666846

Assess the Efficacy and Safety in Volunteers of DCF100, TIB200 and SPR300 vs. Placebo and Control(s) in a UV Pain Model

NCT02666846

Phase 1 Completed 60 enrolled Futura Medical Developments Ltd. Parexel · collab
RandomizedCrossoverQuadruple-blindTreatment

Summary

This is a randomised, double blind, cross over clinical study in healthy human volunteers (including pharmacokinetic \[PK\] sampling and laser Doppler assessment of local blood flow in a subset of up to 6 subjects per cohort of 20) to assess the efficacy and safety of three different topical analgesics (DCF100, TIB200 and SPR300) versus placebo and active control(s) in a model of UV-induced inflammatory pain.

Timeline

Start
2015-03
Primary completion
2015-05
Completion
2015-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Diclofenac Other / unclassified 2 % Topical
Subject Diclofenac Other / unclassified 4 % Topical
Subject Diclofenac Other / unclassified 50 mg Topical
Subject Ibuprofen Small molecule 10 % Topical
Subject Ibuprofen Small molecule 400 mg Topical
Comparator Menthol Small molecule 7 % Topical
Comparator Methyl Salicylate Small molecule 15 % Topical

Indications

No indication recorded.